ContributorsPublishersAdvertisers

FDA Grants Orphan Drug Designation to MT-601 for Pancreatic Cancer Treatment

targetedonc.com
 2022-01-21

Cover picture for the articleWith an orphan drug designation in tow, MT-601 will soon be investigated in combination with chemotherapy in phase 1 clinical trial. The FDA has granted orphan drug designation to MT-601 for the treatment of patients with pancreatic cancer, according to a press release by Marker Therapeutics, Inc.1. MT-601 is...

www.targetedonc.com

Comments / 0

Comments / 0